Pfizer Stock Is A Race Between New Drugs And Old Patents
The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its…
Why Isn’t Eli Lilly Stock Trading At The Top Of Its Peer Group?
The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group’s…
Eli Lilly Stock’s Next Climb Runs Through A Pill, Not Just An Injection
The case for more upside rests on its obesity pill, and what changed is not the drug but…
3 Beaten-Down Healthcare Stocks to Buy in August
Quick Read LLY grew Q1 revenue 56% and won FDA approval for the first oral GLP-1 pill, yet…
The Signs Before Eli Lilly Stock Surged Were All On The Record
Eli Lilly stock ran on a story that was public and dated long before the price moved, and…
Johnson & Johnson Is Becoming A Narrower Company Than You Bought
Management’s plain health care label has slipped out of the lead, and the business now on a separation…
The Real Engine Behind Johnson & Johnson Stock’s Next Climb
While many investors focus on a slowdown in one business segment, they may be overlooking the remarkable growth…
64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital
Quick Read KO and ABBV anchor the portfolio at 25% each, rated Very Safe with payout ratios under…
Everyone Is Watching Eli Lilly Stock’s New Drugs. Here Is the Metric That Vanished
Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how…
The Catch Hiding In Eli Lilly Stock’s Growth Story
Eli Lilly’s obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on…
ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression
AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline…